Stress hormone-mediated invasion of ovarian cancer cells

Clinical Cancer Research

Volumn 12, Issue 2, 2006, Pages 369-375

  Sood, Anil K ^a   Bhatty, Robert ^b   Kamat, Aparna A ^a   Landen, Charles N ^a   Han, Liz ^a   Thaker, Premal H ^a   Li, Yang ^a   Gershenson, David M ^a   Lutgendorf, Susan ^c   Cole, Steven W ^d  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c E11 SSH   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; GELATINASE A; GELATINASE B; HORMONE; HYDROCORTISONE; ISOPRENALINE; MATRIX METALLOPROTEINASE INHIBITOR; NORADRENALIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INFILTRATION; CANCER INVASION; CANCER SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUDE MOUSE; OVARY CANCER; PRIORITY JOURNAL; STRESS; TUMOR GROWTH; TUMOR VOLUME;

ANIMALS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPINEPHRINE; FEMALE; HUMANS; HYDROCORTISONE; ISOPROTERENOL; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; NOREPINEPHRINE; OVARIAN NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 31544465011     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-1698     Document Type: Article

References (64)

1. Ader R. Psychoneuroimmunology. 3rd ed. San Diego (California): Academic Press; 2001.
2. Andersen BL, Kiecolt-Glaser JK, Glaser R. A bio-behavioral model of cancer stress and disease course. Am Psychol 1994;49:389-404.
3. Andersen BL, Farrar WB, Golden-Kreutz DM, et al. Psychological, behavioral, and immune changes after a psychological intervention: a clinical trial. J Clin Oncol 2004;22:3570-80.
4. Glaser R, Kiecolt-Glaser JK. Stress-induced immune dysfunction: implications for health. Nat Rev Immunol 2005;5:243-51.
5. Herbert TB, Cohen S. Stress and immunity in humans: a meta-analytic review. Psychosom Med 1993:55:364-79.
6. Herbert TB, Cohen S. Depression and immunity: a meta-analytic review. Psychol Bull 1993;113. 472-86.
7. Levy SM, Herberman RB, Lippman M, et al. Immunological and psychosocial predictors of disease recurrence in patients with early-stage breast cancer. Behav Med 1991;17:67-75.
8. Stommel M, Given BA, Given CW. Depression and functional status as predictors of death among cancer patients. Cancer 2002;94:2719-27.
9. Coates A, Porzsolt F, Osoba D. Quality of life in oncology practice: prognostic value of EORTC QLQ-C30 scores in patients with advanced malignancy. Eur J Cancer 1997;33:1025-30.
10. Ganz PA, Lee JJ, Siau J. Quality of life assessment. An independent prognostic variable for survival in lung cancer. Cancer 1991;67:3131-5.
11. Seidman AD, Portenoy R, Yao TJ, et al. Quality of life in phase II trials: a study of methodology and predictive value in patients with advanced breast cancer treated with paclitaxel plus granulocyte colony-stimulating factor. J Natl Cancer Inst 1995;87:1316-22.
12. Sanders VM, Straub RH. Norepinephrine, the β-adrenergic receptor, and immunity. Brain Behav Immun 2002;16:290-332.
13. Lutgendorf SK, Cole S, Costanzo E, et al. Stress-related mediators stimulate vascular endothelial growth factor secretion by two ovarian cancer cell lines. Clin Cancer Res 2003;9:4514-21.
14. Schmidt C, Kraft K. β-endorphin and catecholamine concentrations during chronic and acute stress in intensive care patients. Eur J Med Res 1996;1:528-32.
15. Rupp H, Dhalla KS, Dhalla NS. Mechanisms of cardiac cell damage due to catecholamines: significance of drugs regulating central sympathetic outflow. J Cardiovasc Pharmacol 1994;24 Suppl 1:S16-24.
16. Ben-Jonathan N, Arbogast LA, Rhoades TA, et al. Norepinephrine in the rat ovary: ontogeny and de novo synthesis. Endocrinology 1984;115:1426-31.
17. Aguado LI, Ojeda SR. Prepubertal ovarian function is finely regulated by direct adrenergic influences. Role of noradrenergic innervation. Endocrinology 1984;114:1845-53.
18. Aguado LI, Petrovic SL, Ojeda SR. Ovarian β-adrenergic receptors during the onset of puberty: characterization, distribution, and coupling to steroidogenic responses. Endocrinology 1982;110:1124-32.
19. 2-adrenergic theca-interstitial cell recognition sites. Endocrinology 1988;122:1592-602.
20. Lara HE, McDonald JK, Ojeda SR. Involvement of nerve growth factor in female sexual development. Endocrinology 1990;126:364-75.
21. Mayerhofer A, Dissen GA, Costa ME, et al. A role for neurotransmitters in early follicular development: induction of functional follicle-stimulating hormone receptors in newly formed follicles of the rat ovary. Endocrinology 1997;138:3320-9.
22. Lara HE, Porcile A, Espinoza J, et al. Release of norepinephrine from human ovary: coupling to steroidogenic response. Endoc J 2001;15:187-92.
23. Fidler IJ. The pathogenesis of cancer metastasis: the "seed and soil" hypothesis revisited. Nat Rev Cancer 2003;3:453-8.
24. Fidler IJ. Critical determinants of metastasis. Semin Cancer Biol 2002;12:89-96.
25. Sood AK, Coffin JE, Schneider GB, et al. Biological significance of focal adhesion kinase in ovarian cancer: role in migration and invasion. Am J Pathol 2004;165:1087-95.
26. Entschladen F, Lang K, Drell TL, et al. Neurotransmitters are regulators for the migration of tumor cells and leukocytes. Cancer Immunol Immunother 2002;51:467-82.
27. Masur K, Niggemann B, Zanker KS, et al. Norepinephrine-induced migration of SW 480 colon carcinoma cells is inhibited by β-blockers. Cancer Res 2001;61:2866-9.
28. Joseph J, Niggemann B, Zaenker KS, et al. The neurotransmitter γ-aminobutyric acid is an inhibitory regulator for the migration of SW 480 colon carcinoma cells. Cancer Res 2002;62:6467-9.
29. Yang EV, Bane CM, MacCallum RC, et al. Stress-related modulation of matrix metalloproteinase expression. J Neuroimmunol 2002;133:144-50.
30. Wu W, Yamaura T, Murakami K, et al. Involvement of TNF-α in enhancement of invasion and metastasis of colon 26-L5 carcinoma cells in mice by social isolation stress. Oncol Res 1999;11:461-9.
31. Sood AK, Seftor EA, Fletcher MS, et al. Molecular determinants of ovarian cancer plasticity. Am J Pathol 2001;158:1279-88.
32. Sood AK, Fletcher MS, Coffin JE, et al. Functional role of matrix metalloproteinases in ovarian tumor cell plasticity. Am J Obstet Gynecol 2004;190:899-909.
33. Chambers SK. In vitro invasion assays. Ovarian cancer methods and protocols. Bartlett JS, editor. Totowa (New Jersey): Humana Press: 2000. p 179-85.
34. Seftor RE, Seftor EA, De Larco JE, et al. Chemically modified tetracyclines inhibit human melanoma cell invasion and metastasis. Clin Exp Metastasis 1998;16:217-25.
35. Ryan ME, Ramamurthy S, Golub LM. Matrix metalloproteinases and their inhibition in periodontal treatment. Curr Opin Periodontol 1996;3:85-96.
36. Sapolsky RM, Romero LM, Munck AU. How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory, and preparative actions. Endocr Rev 2000;21:55-89.
37. Chrousos GP, Gold PW. The concepts of stress and stress system disorders. Overview of physical and behavioral homeostasis. JAMA 1992;267:1244-52.
38. Nakane T, Szentendrei T, Stern L, et al. Effects of IL-1 and Cortisol on β-adrenergic receptors, cell proliferation, and differentiation in cultured human A549 lung tumor cells. J Immunol 1990;145:260-6.
39. Curran S, Murray GI. Matrix metalloproteinases in tumour invasion and metastasis. J Pathol 1999;189:300-8.
40. Kleiner DE, Stetler-Stevenson WG. Matrix metalloproteinases and metastasis. Cancer Chemother Pharmacol 1999;43 Suppl:S42-51.
41. Ellerbroek SM, Fishman DA, Kearns AS, et al. Ovarian carcinoma regulation of matrix metalloproteinase-2 and membrane type 1 matrix metalloproteinase through β1 integrin. Cancer Res 1999;59:1635-41.
42. Ellerbroek SM, Wu YI, Overall CM, et al. Functional interplay between type I collagen and cell surface matrix metalloproteinase activity. J Biol Chem 2001;276:24833-42.
43. Fishman DA, Bafetti LM, Stack MS. Membrane-type matrix metalloproteinase expression and matrix metalloproteinase-2 activation in primary human ovarian epithelial carcinoma cells. Invasion Metastasis 1996;16:150-9.
44. Davidson B, Goldberg I, Gotlieb WH, et al. High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlate with poor survival in ovarian carcinoma. Clin Exp Metastasis 1999;17:799-808.
45. Stack MS, Ellerbroek SM, Fishman DA. The role of proteolytic enzymes in the pathology of epithelial ovarian carcinoma. Int J Oncol 1998;12:569-76.
46. Bierhaus A, Wolf J, Andrassy M, et al. A mechanism converting psychosocial stress into mononuclear cell activation. Proc Natl Acad Sci U S A 2003;100:1920-5.
47. Greenwald G, Roy S. Follicular development and its control. In Knobil E, Neill J, editors. The physiology of reproduction. New York: Raven Press: 1994. p. 629-724.
48. Nankova B, Kvetnansky R, Hiremagalur B, et al. Immobilization stress elevates gene expression for catecholamine biosynthetic enzymes and some neuropeptides in rat sympathetic ganglia: effects of adrenocorticotropin and glucocorticoids. Endocrinology 1996;137:5597-604.
49. Paredes A, Galvez A, Leyton V, et al. Stress promotes development of ovarian cysts in rats: the possible role of sympathetic nerve activation. Endocrine 1998;8:309-15.
50. Lara HE, Dorfman M, Venegas M, et al. Changes in sympathetic nerve activity of the mammalian ovary during a normal estrous cycle and in polycystic ovary syndrome: studies on norepinephrine release. Microsc Res Tech 2002;59:495-502.
51. Mayerhofer A, Smith GD, Danilchik M, et al. Oocytes are a source of catecholamines in the primate ovary: evidence for a cell-cell regulatory loop. Proc Natl Acad Sci USA 1998;95:10990-5.
52. Fredriksson JM, Lindquist JM, Bronnikov GE, et al. Norepinephrine induces vascular endothelial growth factor gene expression in brown adipocytes through a β-adrenoreceptor/cAMP/protein kinase A pathway involving Src but independently of Erk1/2. J Biol Chem 2000;275:13802-11.
53. 2-adrenergic receptors. Mol Pharmacol 1997;51:711-20.
54. Murphy CJ, Campbell S, Araki-Sasaki K, et al. Effect of norepinephrine on proliferation, migration, and adhesion of SV-40 transformed human corneal epithelial cells. Cornea 1998;17:529-36.
55. Yamanaka Y, Mammoto T, Kirita T, et al. Epinephrine inhibits invasion of oral squamous carcinoma cells by modulating intracellular cAMP. Cancer Lett 2002;176:143-8.
56. Maloney JP, Silliman CC, Ambruso DR, et al. In vitro release of vascular endothelial growth factor during platelet aggregation. Am J Physiol 1998;275:H1054-61.
57. Huber D, Cramer EM, Kaufmann JE, et al. Tissue-type plasminogen activator (t-PA) is stored in Weibel-Palade bodies in human endothelial cells both in vitro and in vivo. Blood 2002;99:3637-45.
58. Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature 2001;411:375-9.
59. Woessner JF, Jr. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 1991;5:2145-54.
60. Rundhaug JE. Matrix metalloproteinases, angiogenesis, and cancer: commentary re: A.C. Lockhart et al., Reduction of wound angiogenesis in patients treated with BMS-275291, a broad spectrum matrix metalloproteinase inhibitor. Clin Cancer Res 2003;9:551-4.
61. Coussens LM, Tinkle CL, Hanahan D, et al. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 2000;103:481-90.
62. Bergers G, Brekken R, McMahon G, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000;2:737-44.
63. Huang S, Van Arsdall M, Tedjarati S, et al. Contributions of stromal metalloproteinase-9 to angiogenesis and growth of human ovarian carcinoma in mice. [comment]. J Natl Cancer Inst 2002;94:1134-42.
64. 4 integrin. J Biol Chem 2004;279:44889-96.